Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02382588 · ClinicalTrials.gov registry record · Phase 2
Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02382588 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 8 participants.
The verdict
NCT02382588, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis. Half the patients will receive the study drug while the other half of the patients will receive the placebo
Interventions
- DRUG gancyclovir gel
- DRUG Hypromellose gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-12-10 |
| Est. Completion | 2020-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02382588
The ClinicalTrials.gov registry entry for NCT02382588 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gancyclovir gel is the first listed.
NCT02382588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02382588 about?
NCT02382588 is a clinical study titled "Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis". The purpose of this study is to evaluate the efficiency of topical gancyclovir 0.15% in the treatment of herpes zoster keratitis. Half the patients will receive the study drug while the other half of the patients will receive the placebo
What is the current status of trial NCT02382588?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-12-10. Estimated completion is 2020-05-11.
What interventions are being tested in trial NCT02382588?
The interventions under investigation include: gancyclovir gel (DRUG), Hypromellose gel (DRUG).
Who is sponsoring clinical trial NCT02382588?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.